Uses of Respira 2: - Asthma - Chronic obstructive pulmonary disease (COPD) Asthma, Chronic obstructive pulmonary disease (COPD) Respira 2 is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.

Short-acting selective & β2-adrenoceptor stimulants

Levosalbutamol is a single isomer beta-2 agonist that differs from racemic salbutamol by elimination of (S)-salbutamol. Levosalbutamol is an effective bronchodilator whose primary mechanism of action is not inhibited by (S)-salbutamol.Thus, when compared with racemic salbutamol, clinically comparable bronchodilation can be achieved. Levosalbutamol produces bronchodilatation through stimulation of beta-2-adrenergic receptors in bronchial smooth muscles, thereby causing relaxation of bronchial muscle fibres.

How to use Levosalbutamol: Check the label for directions before use. Shake the inhaler. While you are breathing in from mouth, press down on the inhaler one time to release the medication and hold your breath for 10 seconds. Repeat until you have inhaled the number of puffs as suggested by the doctor.Afterwards, rinse your mouth thoroughly with water and spit it out. Adult Dose: Oral Adults: 1-2 mg, three times daily. Inhaler: 1-2 puffs as required Nebuliser Solutions Adults: The recommended starting dosage is 0.63 mg administered three to four times a day, every 6 to 8 hours, by nebulization. Patients 12 years of age and older with more severe asthma or patients who do not respond adequately to a dose of 0.63 mg of Levosalbutamol Nebuliser Solution, may benefit from a dosage of 1.25 mg three times a day. Levosalbutamol Nebuliser Solution is supplied in unit-dose ampoules and requires no dilution before administration by nebulization. Child Dose: Oral Children above 12 years: 1-2 mg, three times daily. Children (6 -11 years): 5 ml (1 mg), three times daily. Children (2 -5 years): Up to 0.1 mg/kg body weight (not more than 1 mg) three times daily. Inhaler: 1-2 puffs as required Nebuliser Solutions Child above 12 years old: The recommended starting dosage is 0.63 mg administered three to four times a day, every 6 to 8 hours, by nebulization. Patients 12 years of age and older with more severe asthma or patients who do not respond adequately to a dose of 0.63 mg of Levosalbutamol Nebuliser Solution, may benefit from a dosage of 1.25 mg three times a day. Children (6 months-11 years): The recommended dosage is 0.31 mg administered three times a day, by nebulization. Routine dosing should not exceed 0.63 mg three times a day. Levosalbutamol Nebuliser Solution is supplied in unit-dose ampoules and requires no dilution before administration by nebulization.

Other short-acting sympathomimetic bronchodilators or epinephrine should be used with caution with levosalbutamol. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.

Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.

Common - Throat pain - Nasal congestion (stuffy nose) Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea.

The drug should be used during pregnancy only if the potential benefit justifies the potential risk of the fetus. It is not known whether levosalbutamol is excreted in human milk. Caution should be exercised when oral levosalbutamol is administered to a nursing woman.

Precaution: Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations.

Keep in dry place and away from light and heat. Keep out of the reach of children.

Levosalbutamol is a single isomer beta-2 agonist that differs from racemic salbutamol by elimination of (S)-salbutamol. Levosalbutamol is an effective bronchodilator whose primary mechanism of action is unimpeded by (S)-salbutamol.Thus, when compared with racemic salbutamol, clinically comparable bronchodilation can be achieved with doses that substantially lessen beta-mediated side effects. Levosalbutamol produces bronchodilatation through stimulation of beta-2-adrenergic receptors in bronchial smooth muscles, thereby causing relaxation of bronchial muscle fibres.